Trial · NCT04477590
Interactions of Medicine and Exercise With Meal Timing
NCT04477590, Not applicable, Unknown, University of Castilla-La Mancha
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Interactions of Medicine and Exercise With Meal Timing. Trials, record NCT04477590. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04477590
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Interactions of Medicine and Exercise With Meal Timing
- NCT number
- NCT04477590
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 160 participants, estimated
- Lead sponsor
- University of Castilla-La Mancha
- Conditions
- Metabolic Syndrome, Protection Against, Exercise Training, Metformin, Statins, Angiotensin-Converting-Enzyme Inhibitor, Fasting, Intermittent, Angiotensin Hypertension
- Interventions
- EXERCISE TRAINING WITH OR WITHOUT MEDICATION
- First posted
- 2020-07-20
- Last updated
- 2023-08-25
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Insulin sensitivity assessed using intravenous glucose tolerance test | 12 months | Curves of insulin-mediated glucose clearance, inhibition of lipolysis, and liver glucose output measured with the use of stable isotope infusion. |
| Primary | Post-prandial lipemia assessed by an oral fat tolerance test | 12 months | Rates of appearance and clearance of liver VLDL-TG, Apolipoprotein B, and fatty acids using stable isotopes. |
| Primary | Blood pressure assessed by ECG-gated automated sphygmomanometer | 12 months | Determined immediately after treatments and during the following 24-h using ambulatory blood pressure Holter-type monitors. |
| Primary | Glycemic control assessed by 24-h continuous interstitial glucose monitoring | 36 months | Determined by a patch glucose sensor paired with a glucose monitor. |
| Secondary | Body composition. | 12 months | Determined by bioelectrical impedance to calculate body fat mass and fat free mass. |
| Secondary | Body mass index | 12 months | Determined by body weight (kg) and height (m) to calculate body mass index (kg/m2) |
| Secondary | Maximal oxygen consumption during a graded exercise test to exhaustion, assessed by indirect calorimetry | 12 months | Calculation of cardiorespitarory fitness |
| Secondary | Resting metabolic rate assessed by indirect calorimetry while lying after an overnight fast | 12 months | Using indirect calorimetry and a ventilated canopy system |
| Secondary | Maximal rate of fat oxidation assessed by indirect calorimetry during a submaximal exercise test. | 12 months | Calculated in grams per min during the incremental cycle ergometer test with the use of indirect calorimetry system |
| Secondary | 24-hour monitoring of blood concentrations of metformin, statins, and angiotensin blockers assessed using gas chromatography-mass spectrometry. | 36 months | To study the pharmacokinetics of the habitual medicines used by our subjects during the different experimental conditions |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers12
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04477590
GET https://conductscience.org/api/trials/v1/NCT04477590/registered